July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
April 2025 in “Journal of the Faculty of Medicine Baghdad” Alopecia areata patients may have higher T3 and cortisol levels, suggesting a hormonal link.
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata might help slow down certain cancers.
October 2024 in “La Tunisie Médicale” Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
April 2024 in “Dermatology and therapy” In Denmark from 1995 to 2016, hospital-treated alopecia areata cases increased, mostly affecting women and those over 50.
January 2024 in “International Journal of Homoeopathic Sciences” Individualized homeopathic treatment can effectively treat alopecia areata.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
January 2023 in “Annals of Dermatology” Patients with a specific genetic variant have more severe alopecia areata and higher recurrence rates.
October 2022 in “The Egyptian Journal of Hospital Medicine” Topical corticosteroids are the preferred first treatment for children with Alopecia Areata.
May 2018 in “White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)” Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.
March 2014 in “Journal of The American Academy of Dermatology” Azathioprine may be an effective treatment for severe hair loss.
1 citations
,
January 2015 Personality traits significantly affect the onset, progression, and psychological impact of alopecia areata.
April 2025 in “Egyptian journal of Immunology” Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.
16 citations
,
December 2001 in “Dermatologic Therapy” Alopecia areata has a complex genetic basis that was not fully understood as of 2001.
1 citations
,
August 2021 in “International Journal of Research in Dermatology” There is no significant link between metabolic syndrome and alopecia areata.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
18 citations
,
January 2014 in “Postępy Dermatologii i Alergologii” Personalized treatment plans are important for people with alopecia areata.
16 citations
,
June 2017 in “Advances in Therapy” New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.
15 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” Platelet-Rich Plasma (PRP) could potentially help regrow hair in people with Alopecia Areata, but more research is needed to confirm its effectiveness.
7 citations
,
July 2019 in “International journal of research in dermatology” Intralesional triamcinolone acetonide is more effective than platelet-rich plasma for treating scalp alopecia areata.
1 citations
,
January 2024 in “Annals of Dermatology” COVID-19 may trigger alopecia areata, but more research is needed.
1 citations
,
January 2022 in “The Egyptian Journal of Hospital Medicine ” Cryotherapy and steroid injections are similarly effective and safe for treating alopecia areata.
1 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.
1 citations
,
January 2017 in “The Annals of Clinical and Analytical Medicine” Vitamin D receptor gene changes don't affect alopecia areata risk.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” People with allergies or high eosinophil levels have a higher chance of severe hair loss from alopecia areata, and sudden hair loss can indicate chronic graft-versus-host disease.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
Histopathological confirmation is crucial for accurately diagnosing challenging alopecia areata cases.
March 2025 in “SKIN The Journal of Cutaneous Medicine” Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.